JP2023544832A - １型糖尿病の治療および予防のための方法および組成物 - Google Patents

１型糖尿病の治療および予防のための方法および組成物 Download PDF

Info

Publication number
JP2023544832A
JP2023544832A JP2023521503A JP2023521503A JP2023544832A JP 2023544832 A JP2023544832 A JP 2023544832A JP 2023521503 A JP2023521503 A JP 2023521503A JP 2023521503 A JP2023521503 A JP 2023521503A JP 2023544832 A JP2023544832 A JP 2023544832A
Authority
JP
Japan
Prior art keywords
insulin
mammal
peptide
diabetes
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544832A5 (https=
Inventor
メアリー エス． モリス
パオロ リチャード ディ
Original Assignee
ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー
セントルイス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー, セントルイス ユニバーシティ filed Critical ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー
Publication of JP2023544832A publication Critical patent/JP2023544832A/ja
Publication of JP2023544832A5 publication Critical patent/JP2023544832A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023521503A 2020-10-08 2021-10-05 １型糖尿病の治療および予防のための方法および組成物 Pending JP2023544832A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089122P 2020-10-08 2020-10-08
US63/089,122 2020-10-08
PCT/US2021/053537 WO2022076385A1 (en) 2020-10-08 2021-10-05 Methods and compositions for the treatment and prevention of type 1 diabetes

Publications (2)

Publication Number Publication Date
JP2023544832A true JP2023544832A (ja) 2023-10-25
JP2023544832A5 JP2023544832A5 (https=) 2024-08-21

Family

ID=81126224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521503A Pending JP2023544832A (ja) 2020-10-08 2021-10-05 １型糖尿病の治療および予防のための方法および組成物

Country Status (7)

Country Link
US (1) US20240041986A1 (https=)
EP (1) EP4225352A4 (https=)
JP (1) JP2023544832A (https=)
CN (1) CN116847869A (https=)
AU (1) AU2021356578A1 (https=)
CA (1) CA3193994A1 (https=)
WO (1) WO2022076385A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132530A2 (en) * 2005-01-31 2006-12-14 Leiden University Medical Center Methods and means for use in diagnostics and treatment of diabetes
JP2007528902A (ja) * 2004-03-12 2007-10-18 バイオデル， インコーポレイテッド 迅速に作用する薬物送達組成物
WO2018157202A1 (en) * 2017-02-28 2018-09-07 Biolingus Ip Llc Oil based formulations for sublingual and buccal delivery
JP2019023223A (ja) * 2012-04-16 2019-02-14 イーライ リリー アンド カンパニー インスリンおよびインスリン類似体の薬物動態及び薬力学、ならびに注射部位の疼痛を調節するためのマグネシウム組成物
WO2020021540A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
JP2020507623A (ja) * 2017-02-06 2020-03-12 バイオテンプト・ベー・フェー 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター
JP2020522470A (ja) * 2017-06-01 2020-07-30 イーライ リリー アンド カンパニー 迅速に作用するインスリン組成物
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1409640A (zh) * 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US10905727B2 (en) * 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528902A (ja) * 2004-03-12 2007-10-18 バイオデル， インコーポレイテッド 迅速に作用する薬物送達組成物
WO2006132530A2 (en) * 2005-01-31 2006-12-14 Leiden University Medical Center Methods and means for use in diagnostics and treatment of diabetes
JP2019023223A (ja) * 2012-04-16 2019-02-14 イーライ リリー アンド カンパニー インスリンおよびインスリン類似体の薬物動態及び薬力学、ならびに注射部位の疼痛を調節するためのマグネシウム組成物
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
JP2020507623A (ja) * 2017-02-06 2020-03-12 バイオテンプト・ベー・フェー 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター
WO2018157202A1 (en) * 2017-02-28 2018-09-07 Biolingus Ip Llc Oil based formulations for sublingual and buccal delivery
JP2020522470A (ja) * 2017-06-01 2020-07-30 イーライ リリー アンド カンパニー 迅速に作用するインスリン組成物
WO2020021540A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases

Also Published As

Publication number Publication date
EP4225352A1 (en) 2023-08-16
WO2022076385A1 (en) 2022-04-14
CN116847869A (zh) 2023-10-03
CA3193994A1 (en) 2022-04-14
AU2021356578A9 (en) 2023-07-13
AU2021356578A1 (en) 2023-05-11
EP4225352A4 (en) 2024-01-10
US20240041986A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
Bhavsar et al. Evolution of exenatide as a diabetes therapeutic
EP1988100B1 (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
US8481490B2 (en) Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis
US7888317B2 (en) Glucagon-like peptide-2 and its therapeutic use
JP2017522368A (ja) グルカゴン受容体アンタゴニスト抗体を使用する１型糖尿病の治療方法
US12551537B2 (en) Methods and compositions for the treatment and prevention of type 1 diabetes
Cabré et al. From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
JP2023544832A (ja) １型糖尿病の治療および予防のための方法および組成物
US10105334B2 (en) Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus
WO2020104948A1 (en) Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake
HK40078570A (en) Methods and compositions for the prevention of type 1 diabetes
HK40078570B (en) Methods and compositions for the prevention of type 1 diabetes
WO2017062363A1 (en) Methods of use of betatrophin
TW202135852A (zh) 用於治療肥胖症之使用升糖素和glp-1共促效劑之組合療法
JP2022522461A (ja) 代謝性障害の処置のための組換えタンパク質の使用
CN114929258A (zh) 用于治疗2型糖尿病中的慢性肾病和糖尿病性肾病的胰高血糖素和glp-1协同激动剂
ADLER et al. x. murine diabetes induced through multiple low doses of STZ
HK1125653A (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
HK1153482A (en) Glucagon-like peptide-2 derivatives and their therapeutic use
HK1149720A (en) Glucagon-like peptide-2 and its therapeutic use

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260323